Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (20283)	6/14/2006 6:24:50 PM
From: Qualified Opinion	Respond to of 52153

It's the switching that can become a problem. I doubt a doctor would switch a patient off of a better drug unless asked by a patient. The poor maybe can afford a generic drug versus a name brand drug.

To: Michael Young who wrote (20283)	6/14/2006 8:12:51 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 52153

>>I wonder if a DR has ever been sued for prescribing zocor over lipitor, or a statin over another statin in general. I doubt it. I agree with you Mike. What amazes me is the huge number of males over 45 presenting treatable lipids who are not on ANY statin or treatment despite being under medical care. In the 18 months no less than 5 of my friends have had heart attacks, bypass or stents. None of them were being treated for their lipids. All had insurance and could have afforded the copays. The lack of foresight and care taken to avoid very real heart risks is very unfortunate and intuitively costly to our country. One of the 5 is now unable to do physical work and since that is the type of work he has done is unemployed. Another had bypass at a cost approaching $100K. Insurance paid. They could have bought a lot of statins for that. In general, I do not like suing MD's for malpractice. But not treating willing people (not just men) who are at significant heart risk with statins or something is (or should be) malpractice IMO. ij